Pfizer and Amgen are developing monthly GLP-1 injection drugs for weight loss to replace current weekly treatments [1, 2].
This shift in delivery frequency could significantly increase patient adherence by reducing the burden of constant injections. The transition from weekly to monthly dosing aims to make long-term weight management more convenient and easier for patients to maintain [1, 3].
Currently, the market is dominated by weekly shots such as Wegovy and Zepbound. These medications require a commitment to a seven-day cycle, which can be a barrier for some users. By extending the duration of the drug's effect, Pfizer and Amgen seek to capture a larger share of a rapidly expanding medical sector [1, 2].
The financial stakes for these companies are substantial. The obesity drug market size is estimated at $95 billion [4], a figure that underscores the intense competition between global pharmaceutical giants to dominate the space.
Development efforts focus on modifying the pharmacology of GLP-1 receptor agonists to ensure the medication remains active in the system for 30 days. While weekly versions have proven effective, the goal is to maintain the same efficacy while reducing the number of needles used per year [1, 3].
Pfizer is exploring experimental options including berobenatide as part of its strategy to enter the weight-loss landscape [2]. Amgen is similarly pursuing long-acting formulations to challenge the existing market leaders [1].
If successful, these monthly injections would represent a major shift in how chronic obesity is treated. The move toward less frequent dosing is part of a broader trend in medicine to reduce patient fatigue and improve the quality of life for those on lifelong medication [3].
“Pfizer and Amgen are developing monthly GLP-1 injection drugs for weight loss to replace current weekly treatments.”
The move toward monthly injections represents a strategic attempt to lower the barrier to entry for obesity treatment. By reducing the frequency of administration, drugmakers can potentially increase the total addressable market and improve long-term patient retention in a sector valued at nearly $100 billion. This evolution suggests that the next phase of the GLP-1 race will be defined by delivery convenience rather than just weight-loss percentages.
